Viola Korczak1, Adrienne Kirby2, Naren Gunja3. 1. Royal Prince Alfred Hospital, Sydney, Australia. 2. NHMRC Clinical Trials Centre, University of Sydney. 3. Westmead Hospital, Sydney, Australia; Discipline of Emergency Medicine, Sydney Medical School, University of Sydney, New South Wales, Australia. Electronic address: naren.gunja@sydney.edu.au.
Abstract
OBJECTIVE: Chemical agents commonly used to sedate agitated patients in the emergency department include benzodiazepines, antipsychotics, or a combination of the 2 classes. Our objective was to determine if a class or combination therapy is (1) more effective, as measured by the proportion sedated at 15-20 minutes and the need for repeat sedation, and (2) safer, as measured by the proportion of reported adverse events. METHODS: Systematic literature review and meta-analysis of studies comparing 2 or more chemical agents for sedation of agitated patients in the emergency department were carried out in PubMed, PsycINFO, Embase, and the Cochrane database. Meta-analyses for pairwise comparisons of drug class (benzodiazepine, antipsychotic, or combination) were carried out for each outcome: proportion sedated, need for repeat sedation, and adverse events. RESULTS: Seven studies with 1135 patients were included. At 15-20 minutes, the proportion of patients sedated was greater with combination therapy than benzodiazepines alone (risk ratio [RR] = 1.31, P < .0001). Antipsychotics and combination agents required significantly less repeat sedations than benzodiazepines alone (RR = 0.49, P < .0001 and RR = 0.64, P = .002). There was significant heterogeneity in adverse event data, with respiratory system adverse events (desaturation, and need for airway and ventilatory support) being the most commonly reported. Benzodiazepines were associated with a higher incidence of adverse events than antipsychotics or combination therapy. CONCLUSION: Combination therapy sedated a greater proportion of patients at 15-20 minutes than benzodiazepines alone. Antipsychotics and combination therapy were more effective, requiring less repeat doses for sedation than benzodiazepines. The risk of any adverse event was higher with benzodiazepines.
OBJECTIVE: Chemical agents commonly used to sedate agitated patients in the emergency department include benzodiazepines, antipsychotics, or a combination of the 2 classes. Our objective was to determine if a class or combination therapy is (1) more effective, as measured by the proportion sedated at 15-20 minutes and the need for repeat sedation, and (2) safer, as measured by the proportion of reported adverse events. METHODS: Systematic literature review and meta-analysis of studies comparing 2 or more chemical agents for sedation of agitated patients in the emergency department were carried out in PubMed, PsycINFO, Embase, and the Cochrane database. Meta-analyses for pairwise comparisons of drug class (benzodiazepine, antipsychotic, or combination) were carried out for each outcome: proportion sedated, need for repeat sedation, and adverse events. RESULTS: Seven studies with 1135 patients were included. At 15-20 minutes, the proportion of patients sedated was greater with combination therapy than benzodiazepines alone (risk ratio [RR] = 1.31, P < .0001). Antipsychotics and combination agents required significantly less repeat sedations than benzodiazepines alone (RR = 0.49, P < .0001 and RR = 0.64, P = .002). There was significant heterogeneity in adverse event data, with respiratory system adverse events (desaturation, and need for airway and ventilatory support) being the most commonly reported. Benzodiazepines were associated with a higher incidence of adverse events than antipsychotics or combination therapy. CONCLUSION: Combination therapy sedated a greater proportion of patients at 15-20 minutes than benzodiazepines alone. Antipsychotics and combination therapy were more effective, requiring less repeat doses for sedation than benzodiazepines. The risk of any adverse event was higher with benzodiazepines.
Authors: Ambrose H Wong; Jessica M Ray; Laura D Cramer; Taylor K Brashear; Christopher Eixenberger; Caitlin McVaney; Jeanie Haggan; Mark Sevilla; Donald S Costa; Vivek Parwani; Andrew Ulrich; James D Dziura; Steven L Bernstein; Arjun K Venkatesh Journal: Ann Emerg Med Date: 2021-12-01 Impact factor: 6.762
Authors: Celene Y L Yap; Ya-Seng Arthur Hsueh; Jonathan C Knott; David McD Taylor; Esther W Chan; David C M Kong Journal: Pharmacoecon Open Date: 2018-06
Authors: Ambrose H Wong; Jessica M Ray; Marc A Auerbach; Arjun K Venkatesh; Caitlin McVaney; Danielle Burness; Christopher Chmura; Thomas Saxa; Mark Sevilla; Colin T Flood; Amitkumar Patel; Travis Whitfill; James D Dziura; Kimberly A Yonkers; Andrew Ulrich; Steven L Bernstein Journal: BMJ Open Date: 2020-06-30 Impact factor: 2.692
Authors: David Barbic; Gary Andolfatto; Brian Grunau; Frank X Scheuermeyer; William MacEwan; William G Honer; Hubert Wong; Skye P Barbic Journal: Trials Date: 2018-11-26 Impact factor: 2.279